Tailored Support for
Your Patients Taking Lantus®
Along with their prescription for Lantus®, provide patients information about the
Lantus® Day by Day Guide—an online support tool designed to ease patients into the transition of insulin therapy.
The idea is not to overwhelm them with too many instructions from the start,
but rather to organize the content day by day, so patients can build their
knowledge and confidence.
The Lantus® Day by Day Guide includes motivational tips from other Lantus®
users on such topics as: how to use insulin, why you should keep a blood
sugar log, and the importance of maintaining a daily routine. And there are
opportunities for your patients to obtain personalized support from Certified Diabetes Educators*.
When you prescribe Lantus® let your patients know they can visit the Lantus®
Day by Day Guide to find answers to frequently asked questions they may
have about starting insulin therapy. The Lantus® Day by Day Guide gives your
patients a place where they can receive relevant information in digestible bits,
as well as extra encouragement, in between office visits, and at every step
along their way to better glycemic control.
Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)
Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and pediatric patients with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.
Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.
Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)
Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.
Warnings and Precautions
Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Do not dilute or mix Lantus® with any other insulin or solution. If mixed or
diluted, the solution may become cloudy, and the onset of action/time to peak effect
may be altered in an unpredictable manner. Do not administer Lantus® via an
insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices
and needles must not be shared between patients.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.
A reduction in the Lantus® dose may be required in patients with renal or hepatic
Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of
thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of
heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and
close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients
taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).
Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.
Important Safety Information for Lantus®
Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.
here for Full Prescribing Information for Lantus®.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.